The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | High-risk CCUS as a distinct disease entity: implications for clinical trials
Zhuoer Xie, MD, MS, Moffitt Cancer Center, Tampa, FL, discusses findings from a recent study showing that patients with high-risk clonal cytopenia of undetermined significance (CCUS) have clinical features comparable with lower-risk myelodysplastic syndromes (MDS). Dr Xie highlights that, despite similar disease-related event rates, patients with high-risk CCUS are often excluded from clinical trials. She emphasizes that clinical trial eligibility should be guided by biological risk rather than diagnostic labels, viewing CCUS, MDS, and acute myeloid leukemia (AML) as a disease continuum. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
